Retrospective Cohort Study

Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China

Hao Cui, Jian-Xin Cui, Yu-Ning Wang, Bo Cao, Huan Deng, Ke-Cheng Zhang, Tian-Yu Xie, Wen-Quan Liang, Yi Liu, Lin Chen, Bo Wei

Hao Cui, Tian-Yu Xie, School of Medicine, Nankai University, Tianjin 300071, China
Jian-Xin Cui, Bo Cao, Huan Deng, Ke-Cheng Zhang, Wen-Quan Liang, Yi Liu, Lin Chen, Bo Wei, Department of General Surgery, Institute of General Surgery, Chinese PLA General Hospital, Beijing 100853, China
Yu-Ning Wang, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Corresponding author: Bo Wei, MD, PhD, Chief Doctor, Professor, Staff Physician, Department of General Surgery, Institute of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. 18431143691@163.com

Abstract

BACKGROUND
The potential survival benefit of neoadjuvant chemotherapy (NC) in patients with advanced gastric cancer has been widely recognized. With the development of minimally invasive surgery, which is represented by laparoscopy, the effect of NC on the safety of laparoscopic gastrectomy remains to be further explored.

AIM
To compare the short-term outcomes of laparoscopic total gastrectomy (LTG) after NC (NC-LTG) with LTG alone.

METHODS
A total of 92 patients who underwent NC-LTG and 381 patients who received LTG alone at the Chinese PLA General Hospital between September 2015 and September 2020 were retrospectively included in our study. We used propensity-score matching (PSM) to balance baseline bias. After 1:1 PSM, 73 patients were included in each group with no statistically significant difference in baseline characteristics.

RESULTS
The NC-LTG group exhibited a longer operation time (244.10 ± 48.13 min vs 225.74 ± 45.33 min, P = 0.019) and increased intraoperative blood loss [150 (100-300) mL vs 100 (100-200) mL, P = 0.011] compared to the LTG group. The 30-d
postoperative morbidity of the NC-LTG group was 20.5% (15/73), and that of the LTG group was 13.7% (10/73). There were no significant differences in 30-d severe complication rates or anastomotic leakage rates. Subgroup analysis showed that the patients with pTNM (pathological tumor-node-metastasis classification) T0N0-II in the NC-LTG group underwent a longer operation than the LTG group, while no significant difference was found in any perioperative index for the pTNM III patients. A multivariate analysis showed that an operation time longer than 240 min was an independent risk factor (odds ratio = 3.021, 95% confidence interval: 1.160-7.868, \( P = 0.024 \)) while NC was not an independent risk factor for postoperative complications in LTG.

**CONCLUSION**

Despite a longer operation time and more blood loss after NC-LTG, which indicate surgical difficulty, NC-LTG exhibits acceptable short-term outcomes compared to LTG, suggesting the safety and feasibility of NC-LTG.

**Key Words:** Neoadjuvant chemotherapy; Gastric cancer; Laparoscope; Total gastrectomy; Morbidity

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Neoadjuvant chemotherapy (NC) and laparoscopic gastrectomy are crucial parts of integrated perioperative treatment for gastric cancer. However, whether NC significantly affects surgical safety or postoperative complications of laparoscopic gastrectomy, especially laparoscopic total gastrectomy (LTG), remains unclear. In our study, we used the propensity-score matching method to compare short-term outcomes between LTG after NC (NC-LTG) and LTG alone. We found that despite a longer operation time and more blood loss in NC-LTG, which indicate surgical difficulty, NC-LTG shows acceptable short-term outcomes compared to LTG, illustrating its safety and feasibility.

**Citation:** Cui H, Cui JX, Wang YN, Cao B, Deng H, Zhang KC, Xie TY, Liang WQ, Liu Y, Chen L, Wei B. Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China. *World J Gastrointest Surg* 2021; 13(5): 429-442

URL: https://www.wjgnet.com/1948-9366/full/v13/i5/429.htm

DOI: https://dx.doi.org/10.4240/wjgs.v13.i5.429

**INTRODUCTION**

Gastric cancer is one of the most common malignant tumors and is the fifth most frequently diagnosed tumor and third leading cause of cancer-related deaths, according to GLOBOCAN data updated in 2018[1]. People in East Asia are prone to suffer from gastric cancer due to their dietary habits and genetic background. Compared to those in Japan and South Korea, patients in China have lower morbidity but higher mortality, which has become a heavy burden on public health. This outcome is primarily attributed to the decreased popularity of early gastric cancer screening, which leads to a higher proportion of patients with advanced gastric cancer upon diagnosis[2,3].

To improve long-term survival for patients with advanced gastric cancer, integrated perioperative treatment based on radical surgery has recently received gradually increasing attention. Neoadjuvant chemotherapy (NC), a crucial part of integrated perioperative treatment, has attracted attention as an area of frontier research[4,5]. Since the MAGIC trial[6] first demonstrated that NC significantly improves progression-free and overall survival of gastric cancer, an increasing number of high-grade evidence-based clinical trials have shown a potential survival benefit of receiving NC due to preoperative downstaging of tumors, appropriate NC regimens, etc. However, in our experience, NC might lead to perigastric tissue effusion and fragility, and the anatomic interval is fuzzy. Therefore, whether NC affects surgical safety remains
With the application of laparoscopy for gastrectomy gradually gaining favour, and because of the increasing trend of middle-upper gastric cancer in China,[13] laparoscopic total gastrectomy (LTG) has become a common surgical approach, and its surgical safety and feasibility for clinical stage I gastric cancer patients have been demonstrated by the CLASS-02 and KLASS-03 trials[14,15]. Many large-volume retrospective studies have demonstrated that LTG has comparable short- and long-term outcomes to open total gastrectomy in advanced gastric cancer patients[16-18]. Therefore, we sought to evaluate the short-term outcomes of LTG after NC (NC-LTG) vs LTG alone for pathological stage T0N0-III patients, which can provide reasonable data support for broader application of NC-LTG.

MATERIALS AND METHODS

Patients
This was a single institution retrospective analysis using prospectively collected clinicopathological data from the Department of General Surgery, Chinese PLA General Hospital First Medical Center. The eligible criteria included: (1) Histologically proven gastric cancer by preoperative gastroscopy with a tumor location suitable for LTG; (2) No metastasis according to a preoperative positron emission tomography/computed tomography scan or enhanced abdominal computed tomography scan; (3) Pathological tumor stage ranged from T0N0-III based on the UICC/AJCC 8th guideline[19]; (4) No conversion to open total gastrectomy; and (5) Integrated clinical and pathological data. Patients who had severe comorbidities [American Society of Anesthesiologists score (ASA) > III] or other organ resections were excluded from our study. According to the aforementioned criteria, we collected the data for 473 patients who underwent LTG between September 2015 and September 2020. Among these patients, 92 individuals underwent NC-LTG (the NC-LTG group), while 381 were treated only by LTG. We adopted double-drug NC regimens, including SOX (TS-1 + oxaliplatin) or XELOX (Xeloda + oxaliplatin), and surgery was performed on patients in the NC-LTG group 4 to 6 wk after the completion of chemotherapy.

Surgical approach
All patients recruited into this study underwent LTG plus D2 lymphadenectomy. The surgical team had extensive experience and perform at least 50 laparoscopic gastrectomies per year; therefore, they each had already overcome the learning curve. The surgical procedure and lymph node dissection were performed in accordance with the Japanese gastric cancer treatment guideline (Ver. 5)[20]. D2 lymphadenectomy was performed, including Nos. 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, and 12a, but not No. 10. After the intracorporeal procedure, a 7-cm incision made from the middle of the epigastrium was needed to remove the specimen and finish extracorporeal Roux-en-Y anastomosis using a circular stapler for esophagojejunostomy and a linear stapler for jejunojejunostomy.

Data collection and perioperative indicators
Baseline characteristics were recorded, including sex, age, body mass index, ASA score, history of abdominal surgery, tumour diameters, pathological tumour stage, tumour differentiation, and the presence of nerve and vascular invasion. During surgery, we determined the estimated blood loss and analyzed the operation time data to evaluate surgical difficulty. We used a propensity-score matching (PSM) method with a 1:1 ratio to reduce baseline bias.

Postoperative indicators are crucial to reflect short-term outcomes. The first flatus day and postoperative hospitalization day were recorded to represent postoperative recovery. Surgical complications occurring within 30 d after the operation were considered in this study. We used the Clavien-Dindo (C-D) classification[21] to evaluate the severe degree of 30-d morbidity. Due to the limitations of retrospective studies, C-D grade I, which was defined as a complication without medical intervention, was not included with data on total morbidity. C-D grade ≥ IIIa was regarded as a severe complication. Anastomotic leakage was observed by the colour and quantity of drainage and was diagnosed by radiological gastroenterography or a second surgery. The R0 resection rate and number of retrieved lymph nodes were acquired from pathological results.
Statistical analysis

SPSS 26.0 (SPSS Inc., Chicago, IL, United States) was used to conduct statistical analyses. Categorical variables were analyzed by Chi-square or Fisher’s exact test, while continuous data were analyzed by Student’s t-test or the Mann-Whitney U test. Because a significant difference in partial baseline characteristics was observed between the NC-LTG and LTG groups, we performed a PSM method with a 1:1 ratio and 0.02 matching tolerance to eliminate baseline bias. Univariate and multivariate logistic regression analyses were used to evaluate risk factors for postoperative complications. A P value < 0.05 was considered statistically significant.

RESULTS

Baseline characteristics

Table 1 shows the baseline characteristics of the NC-LTG and LTG groups. We found that the ASA score was significantly different between the two groups (P = 0.023). After 1:1 matching using a generalized estimating equation model based on the abovementioned clinicopathological indicators, 73 patients in each group were ultimately screened, and no significant difference was found in any of the baseline characteristics, which are presented in Table 2. In the NC-LTG cohort, 73 patients were administered the SOX (n = 57) or XELOX (n = 16) regimens before LTG, and the chemotherapy effect and potential surgical opportunity were estimated by a multidisciplinary team. In the matched LTG cohort, 73 patients underwent LTG without preoperative chemotherapy or radiotherapy.

Intraoperative indicators and postoperative recovery

The NC-LTG group had a longer operation time (244.10 ± 48.13 min vs 225.74 ± 45.33 min, P = 0.019) and increased blood loss [150 (100-300) mL vs 100 (100-200) mL, P = 0.011], with a significant difference compared to the LTG group. No significant disparity was found in the number of retrieved lymph nodes or the R0 resection rate between the two groups (P > 0.05). When analyzed for postoperative recovery, the NC-LTG and LTG groups had comparable first flatus days and postoperative hospitalization days with no significant difference.

30-d postoperative morbidity and mortality

No patients in the LTG group died on perioperative days, while one patient in the NC-LTG group died due to septic shock 4 d after surgery. Although the rate of complications [20.5% (15/73)] in the NC-LTG group was higher than that in the LTG group [13.7% (10/73)], the difference was not significant (P = 0.272). Four patients (two patients in the LTG group and two patients in the NC-LTG group) experienced anastomotic leakage from the esophagojejunostomy site. One patient underwent laparotomy to close the leakage, and the other patients were attended by expectant therapy. The degree of complication severity was evaluated according to the C-D classification, which is shown in Table 3.

We divided all enrolled patients into two subgroups according to different pathological TNM stages. After baseline characteristics showed no significant difference between the NC-LTG and LTG groups in any subgroup, we evaluated the perioperative indexes. In pTNM T0N0-II patients, NC-LTG exhibited a longer operation time compared to the LTG group, while other indicators, including estimated blood loss, number of retrieved lymph nodes, R0 resection rate, first flatus day, postoperative hospitalized day, overall morbidity, and severe morbidity showed no significant differences between the two groups, as shown in Table 4. For pTNM III patients in the two groups, no significant difference was found in any of the indicators mentioned, as presented in Table 5.

Risk factors for overall complications after LTG

Table 6 shows the univariate and multivariate logistic regression results used to explore risk factors for postoperative complications after LTG. NC was not associated with postoperative complications, as shown by univariate analysis (odds ratio = 1.629, 95% confidence interval: 0.678-3.913, P = 0.275). We placed indicators obtained by univariate regression with P > 0.25 into the multivariate analysis and found that an operation time ≥ 240 min was a significant independent risk factor for overall postoperative complication (odds ratio = 3.021, 95% confidence interval: 1.160-7.868, P = 0.024).
| Clinical characteristic | NC-LTG group (n = 92) | LTG group (n = 381) | P value |
|--------------------------|------------------------|---------------------|---------|
| Sex                      |                        |                     | 0.109   |
| Male                     | 68                     | 310                 |         |
| Female                   | 24                     | 71                  |         |
| Age (yr, mean ± SD)      | 58.87 ± 10.28          | 59.85 ± 11.40       | 0.452   |
| BMI (kg/m², mean ± SD)   | 23.03 ± 2.97           | 23.79 ± 3.65        | 0.065   |
| History of abdominal surgery |                    |                     | 0.368   |
| Yes                      | 17                     | 56                  |         |
| No                       | 75                     | 325                 |         |
| ASA grade                |                        |                     | 0.023   |
| I                        | 10                     | 3                   |         |
| II                       | 72                     | 336                 |         |
| III                      | 10                     | 42                  |         |
| Tumor diameter, cm (median, IQR) | 4.00 (3.00-6.37)     | 5.00 (3.00-6.50)    | 0.108   |
| pT                       |                        |                     | 0.433   |
| T0-T1                    | 12                     | 63                  |         |
| T2                       | 15                     | 38                  |         |
| T3                       | 52                     | 206                 |         |
| T4                       | 13                     | 74                  |         |
| pN                       |                        |                     | 0.129   |
| N0                       | 36                     | 127                 |         |
| N1                       | 15                     | 54                  |         |
| N2                       | 18                     | 73                  |         |
| N3                       | 23                     | 127                 |         |
| pTNM                     |                        |                     | 0.600   |
| O-I                      | 20                     | 80                  |         |
| II                       | 28                     | 105                 |         |
| III                      | 44                     | 196                 |         |
| Differentiation          |                        |                     | 0.829   |
| Well/moderate            | 44                     | 187                 |         |
| Poor/undifferentiated    | 48                     | 194                 |         |
| Nerve invasion           |                        |                     | 0.150   |
| Yes                      | 29                     | 151                 |         |
| No                       | 63                     | 250                 |         |
| Vascular invasion        |                        |                     | 0.220   |
| Yes                      | 28                     | 142                 |         |
| No                       | 64                     | 239                 |         |

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range; TNM: Tumor-node-metastasis.
Table 2 Baseline characteristics of laparoscopic total gastrectomy after neoadjuvant chemotherapy group and laparoscopic total gastrectomy group after propensity-score matching

| Clinical characteristic | NC-LTG group (n = 73) | LTG group (n = 73) | P value |
|-------------------------|------------------------|-------------------|---------|
| Sex                     |                        |                   | 0.843   |
| Male                    | 57                     | 56                |         |
| Female                  | 16                     | 17                |         |
| Age (yr, mean ± SD)     | 59.56 ± 10.23          | 58.48 ± 12.35     | 0.565   |
| BMI (kg/m², mean ± SD)  | 23.16 ± 2.75           | 23.06 ± 3.91      | 0.860   |
| History of abdominal surgery |                  |                   | 1.000   |
| Yes                     | 14                     | 14                |         |
| No                      | 59                     | 59                |         |
| ASA grade               |                        |                   | 0.646   |
| I                       | 6                      | 2                 |         |
| II                      | 61                     | 67                |         |
| III                     | 6                      | 4                 |         |
| Tumor diameter, cm (median, IQR) | 4.5 (3.0-6.0)   | 4.0 (3.0-6.0)     | 0.716   |
| pT                      |                        |                   | 0.706   |
| T0-T1                   | 8                      | 14                |         |
| T2                      | 12                     | 9                 |         |
| T3                      | 42                     | 37                |         |
| T4                      | 11                     | 13                |         |
| pN                      |                        |                   | 0.917   |
| N0                      | 26                     | 32                |         |
| N1                      | 14                     | 5                 |         |
| N2                      | 16                     | 16                |         |
| N3                      | 17                     | 20                |         |
| pTNM                    |                        |                   | 0.710   |
| 0-I                     | 14                     | 17                |         |
| II                      | 25                     | 23                |         |
| III                     | 34                     | 33                |         |
| Differentiation         |                        |                   | 0.619   |
| Well/moderate           | 37                     | 34                |         |
| Poor/undifferentiated   | 36                     | 39                |         |
| Nerve invasion          |                        |                   | 0.730   |
| Yes                     | 25                     | 27                |         |
| No                      | 48                     | 46                |         |
| Vascular invasion       |                        |                   | 0.210   |
| Yes                     | 26                     | 19                |         |
| No                      | 47                     | 54                |         |

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range; TNM: Tumor-node-metastasis.
DISCUSSION

NC is currently a hotspot of integrated therapy for advanced gastric cancer. Many studies have demonstrated that preoperative chemotherapy previously applied in European countries can reduce the tumour clinical stage and even lead to pathological complete response, showing oncological benefit because of the elevated R0 resection rate[6,22]. People in East Asia have a high risk of gastric cancer, and radical gastrectomy followed by postoperative chemotherapy is still regarded as the standard treatment for advanced gastric cancer patients[20,23]. However, a lower incidence of tolerance and compliance in patients who receive chemotherapy after gastrectomy represents an obstacle to prolonged survival. NC may change this situation; therefore, continuous high-quality randomized controlled trial studies, such as JCOG-0405[24], JCOG-1002[25], and JCOG-0501[26] studies conducted by the Japan Clinical Oncology Group, the RESOLVE[7] and the RESONANCE[9] trials conducted in China, and the PRODIGY trial[8] conducted in South Korea, have been recently performed, providing theoretical support for the optimal selection of NC regimen and exploring appropriate indications, especially for patients in East Asia.

There is consistent controversy regarding whether NC increases surgical difficulty. With respect to LTG, CLASS-02 and KLASS-03 studies[14,15] simultaneously demonstrated that LTG and open total gastrectomy (OTG) exhibited comparable short-term outcomes in clinical stage I patients. Large-scale retrospective studies also showed that LTG was comparable to OTG in terms of short- and long-term outcomes in both early and advanced gastric cancer patients[18]. Recently, surgeons have started to focus on the effects of NC associated with laparoscopic gastrectomy. Li et al[27] found that laparoscopic distal gastrectomy after NC significantly reduced postoperative complication rates and led to better chemotherapy tolerance than open distal gastrectomy. The STOMACH trial [28] conducted by European multi-institutional medical centres showed that open surgery or LTG after NC led to comparable short-term outcomes and non-inferiority in terms of 1-year overall survival. Shuai et al[29] demonstrated that NC was safe and feasible after laparoscopic gastrectomy for advanced gastric cancer, while it increased the R0 resection rate and reduced tumour stage. An international cohort study also presented similar results[30]. However, few studies have reported the effect of NC on the short-term efficacy of LTG, and this issue requires further evaluation. In our study, we present our single institution data aimed at determining the perioperative safety of NC-LTG compared to LTG alone in gastric cancer patients.

There is consistent controversy regarding whether NC increases surgical difficulty. Some perspectives consider that NC may cause perigastric tissue oedema and fibrillation, lead to fragility of normal tissue, a fuzzy anatomic interval, etc., resulting in surgical complications[31]. An initial study conducted by our medical centre demonstrated that gastrectomy after NC exhibited a longer operation time and a higher proportion of patients with estimated blood loss greater than 200 mL compared to those undergoing surgery without chemotherapy[32]. However, Shuai et al[29] indicated that NC did not significantly increase the surgical time or quantity of blood lost during laparoscopic gastrectomy. In the present study, the NC-LTG group had a significantly prolonged surgical time and more blood loss than the LTG group. Results of the subgroup analysis showed that patients in pathological stage T0N0-II in the NC-LTG group had a longer operation time, while no significant difference was found in patients at pathological stage III in the LTG and NC-LTG groups. In terms of estimated blood loss, there was no significant difference between the two groups, regardless of the pathological stage of the patients. The potential reason for this outcome might be that patients with early pathological stages and receiving NC were sensitive to the chemotherapy or endured a longer cycle of preoperative treatment, causing tissue exudation and oedema, which increased the difficulty of the surgery. In contrast, early-stage patients in the LTG group had relatively easy surgeries.

Radical surgical resection and a sufficient number of retrieved lymph nodes can remarkably promote long-term prognosis in gastric cancer. Our research found that the R0 resection rate was 90.4% (66/73) in the NC-LTG group and 94.5% (69/73) in the LTG group with no obvious imparity, indicating that NC-LTG has an effect on radical resection equal to the effect of LTG alone. Lymph nodes can better reflect the oncological quality of resection. In our study, no significant difference was found in the number of lymph nodes retrieved between the NC-LTG and LTG groups, which demonstrates that NC-LTG and LTG have comparable capacities for lymph node resection.
Table 3 Surgical indicators in perioperative days between laparoscopic total gastrectomy after neoadjuvant chemotherapy and laparoscopic total gastrectomy group

| Variable                             | NC-LTG group (n = 73) | LTG group (n = 73) | P value |
|--------------------------------------|-----------------------|--------------------|---------|
| Surgical time, min (mean ± SD)       | 244.10 ± 48.13        | 225.74 ± 45.33     | 0.019   |
| Blood loss, mL (median, IQR)         | 150 (100-300)         | 100 (100-200)      | 0.011   |
| Retrieved lymph nodes, n (mean ± SD)| 31.14 ± 11.81         | 32.21 ± 12.12      | 0.593   |
| Fist flatus day, d (mean ± SD)       | 4.25 ± 1.11           | 4.27 ± 1.10        | 0.896   |
| R0 resection rate, n (%)             | 3 (4.1)               | 3 (4.1)            | 1.000   |
| Postoperative day, d (median, IQR)   | 9.0 (7.0-11.0)        | 8.0 (7.0-11.0)     | 0.602   |
| Total complication rate, n (%)       | 15 (20.5)             | 10 (13.7)          | 0.272   |

Clavien-Dindo classification

Grade II
- Anastomosis leakage: 2 vs. 1
- Lymphatic leakage: 1 vs. 2
- Abdominal infection: 1 vs. 0
- Ileus: 1 vs. 0
- Anemia: 3 vs. 1
- Pneumonia: 1 vs. 0
- Hypoproteinemia: 2 vs. 2

Grade III
- Deep venous thrombosis: 1 vs. 0
- Anastomosis leakage: 0 vs. 1
- Intestinal leakage: 0 vs. 1
- Seroperitoneum: 0 vs. 1
- Abdominal hemorrhage: 0 vs. 1

Grade IV
- Cerebral infraction: 2 vs. 0

Grade V
- Severe pneumonia: 1 vs. 0
- Severe complication rate, n (%): 4 (5.5) vs. 4 (5.5) 1.000

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; IQR: Interquartile range.

Postoperative complications are crucial indicators for evaluating short-term outcomes. Previous studies have shown that there was no significant difference in postoperative morbidity caused by NC after gastrectomy[11,33-35]; however, few studies have focused on short-term outcomes after LTG with NC. In this study, we found that the overall postoperative morbidity in the NC-LTG group was 20.5% (15/73), while it was 13.7% (10/73) in the LTG group. The subgroup analysis illustrated that for patients in pathological stage T0N0-II or III, no significant correlation was observed between overall or severe morbidity and NC. Moreover, anastomosis leakage is a common complication after total gastrectomy that is correlated with perioperative mortality and further recurrence[36,37]. A single-arm study from Japan showed that the anastomosis leakage rate after laparoscopic total or proximal gastrectomy for early-stage patients was 2.5%[38]. Another large-scale retrospective study demonstrated that the anastomosis leakage rate in stage I patients was 5.4%, while that in stages II-IV patients was 5.7% after LTG[39]. In the present study, the anastomosis leakage rate in both the NC-LTG and LTG groups was not significantly different at 2.7%. Based on the above research, the occurrence of anastomosis leakage did not seem to be associated with NC in LTG, indicating that...
Table 4 Clinical characteristics and surgical indicators in pTNM 0-II patients between laparoscopic total gastrectomy after neoadjuvant chemotherapy and laparoscopic total gastrectomy group

| Variable                        | NC-LTG group (n = 39) | LTG group (n = 40) | P value |
|---------------------------------|-----------------------|-------------------|---------|
| Sex                             |                       |                   | 0.560   |
| Male                            | 28                    | 31                |         |
| Female                          | 11                    | 9                 |         |
| Age (yr, mean ± SD)             | 59.56 ± 10.67         | 58.73 ± 12.08     | 0.745   |
| BMI (kg/m², mean ± SD)          | 23.08 ± 2.71          | 22.20 ± 4.25      | 0.275   |
| ASA grade                       |                       |                   | 0.508   |
| I                               | 3                     | 1                 |         |
| II                              | 31                    | 38                |         |
| III                             | 5                     | 1                 |         |
| Surgical time, min (mean ± SD)  | 249.38 ± 48.62        | 223.85 ± 50.13    | 0.024   |
| Blood loss, mL (median, IQR)    | 100 (100-200)         | 100 (100-150)     | 0.067   |
| Retrieved lymph nodes, n (mean ± SD) | 30.67 ± 11.53       | 32.73 ± 13.07     | 0.461   |
| Fist flatus day, d [(median, IQR)] | 4.0 (3.0-5.0)        | 4.5 (3.0-5.0)     | 0.741   |
| R0 resection rate, n (%)        | 2 (5.1)               | 0 (0)             | 0.241   |
| Postoperative day, d [(median, IQR)] | 9.0 (7.0-10.0)       | 9.0 (7.0-11.0)    | 0.724   |
| Total complication rate, n (%)  | 9 (23.1)              | 4 (10.0)          | 0.117   |
| Severe complication rate, n (%) | 2 (5.1)               | 1 (2.5)           | 0.982   |

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range.

application of LTG is safe and feasible after NC.

Some inherent limitations exist in this research. First, this was a single institution retrospective study with potential selection bias. Prospective studies can be conducted based on our previous results to provide more reliable evidence. Second, even though we utilized the PSM method to reduce baseline characteristic bias between the NC-LTG and LTG groups, there were still some potential factors that may have influenced the short-term outcomes. Third, due to uncertainty of the preoperative clinical stage, we recorded only postoperative pathological stage to ensure that we could evaluate perioperative outcomes after LTG with NC or not at the current pathological stage. The final limitation is that we unified pTNM T0N0-II stage patient data into one group due to the small sample size in the subgroup analysis. Further studies need to expand the sample size to analyze significant differences in perioperative indicators based on explicit pathological stage.

Despite these limitations, to our knowledge, few preliminary studies in addition to that presented herein, have reported short-term effects of NC-LTG in China. After PSM, we found that although NC-LTG was found to be associated with prolonged operation time and increased intraoperative blood loss, which increased surgical difficulty to a certain extent, no significant difference was observed between NC-LTG and LTG with respect to the number of retrieved lymph nodes or 30-d postoperative morbidity, indicating that the NC does not increase the risk of LTG and is a safe and feasible operation. However, the long-term oncology efficacy needs to be further evaluated.

**CONCLUSION**

Despite a longer operation time and more blood loss after NC-LTG, which indicate surgical difficulty, NC-LTG exhibits acceptable short-term outcomes compared to LTG, illustrating the safety and feasibility of NC-LTG.
### Table 5 Clinical characteristics and surgical indicators in pTNM III patients between laparoscopic total gastrectomy after neoadjuvant chemotherapy and laparoscopic total gastrectomy group

| Variable                              | NC-LTG group (n = 34) | LTG group (n = 33) | P value |
|---------------------------------------|-----------------------|--------------------|---------|
| Sex                                    |                       |                    |         |
| Male                                   | 29                    | 25                 | 0.324   |
| Female                                 | 5                     | 8                  |         |
| Age (yr, mean ± SD)                    | 59.56 ± 9.84          | 58.18 ± 12.85      | 0.623   |
| BMI (kg/m², mean ± SD)                 | 23.24 ± 2.85          | 24.09 ± 3.20       | 0.250   |
| ASA grade                              |                       |                    | 0.160   |
| I                                      | 3                     | 1                  |         |
| II                                     | 30                    | 29                 |         |
| III                                    | 1                     | 3                  |         |
| Surgical time, min (mean ± SD)         | 237.44 ± 46.86        | 228.03 ± 39.39     | 0.378   |
| Blood loss, mL (median, IQR)           | 200 (100-500)         | 100 (100-200)      | 0.078   |
| Retrieved lymph nodes, n (mean ± SD)   | 32.09 ± 12.32         | 31.58 ± 11.04      | 0.858   |
| Fist flatus day, d [median, (IQR)]     | 4.0 (3.0-5.0)         | 4.0 (3.0-5.0)      | 0.844   |
| R0 resection rate, n (%)               | 1 (2.9)               | 3 (9.1)            | 0.288   |
| Postoperative day, d [median, (IQR)]   | 9.5 (7.0-11.0)        | 8.0 (7.0-9.5)      | 0.321   |
| Total complication rate, n (%)         | 6 (17.6)              | 6 (18.2)           | 0.954   |
| Severe complication rate, n (%)        | 2 (5.9)               | 3 (9.1)            | 0.617   |

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range.
Table 6 Univariate and multivariate logistic regression analyses for postoperative complications in laparoscopic total gastrectomy patients

| Factor                      | Univariate analysis | P value | Multivariate analysis | P value |
|-----------------------------|---------------------|---------|-----------------------|---------|
|                             | OR                  | 95%CI   | OR                    | 95%CI   |
| Sex                         |                     |         |                       |         |
| Male                        | Ref                 |         | Ref                   |         |
| Female                      | 1.807               | 0.700-4.666 | 2.601            | 0.906-7.465 |
| Age                         | 0.215               |         |                       | 0.159   |
| < 60                        | Ref                 |         |                       |         |
| ≥ 60                        | 0.574               | 0.239-1.380 | 0.519              | 0.208-1.292 |
| BMI (kg/m²)                 |                     |         |                       |         |
| < 25                        | Ref                 |         |                       |         |
| ≥ 25                        | 1.277               | 0.517-3.152 |                   |         |
| Neoadjuvant chemotherapy    |                     |         |                       |         |
| No                          | Ref                 |         |                       |         |
| Yes                         | 1.629               | 0.678-3.913 |                   |         |
| ASA score                   |                     |         |                       |         |
| < II                        | Ref                 |         |                       |         |
| ≥ II                        | 1.474               | 0.173-12.538 |                   |         |
| Tumor diameter (cm)         |                     |         |                       |         |
| < 5                         | Ref                 |         |                       |         |
| ≥ 5                         | 1.747               | 0.733-4.162 | 2.049              | 0.793-5.296 |
| Operation time (min)        |                     |         |                       |         |
| < 240                       | Ref                 |         |                       |         |
| ≥ 240                       | 2.726               | 1.093-6.799 | 3.021              | 1.160-7.868 |
| Estimated blood loss (mL)   |                     |         |                       |         |
| ≤ 200                       | Ref                 |         |                       |         |
| > 200                       | 1.750               | 0.652-4.699 |                   |         |
| Vascular invasion           |                     |         |                       |         |
| No                          | Ref                 |         |                       |         |
| Yes                         | 1.328               | 0.537-3.283 |                   |         |
| Nerve invasion              |                     |         |                       |         |
| No                          | Ref                 |         |                       |         |
| Yes                         | 1.533               | 0.639-3.677 |                   |         |

CI: Confidence interval; OR: Odds ratio; BMI: Body mass index; ASA: American Society of Anesthesiologists.

ARTICLE HIGHLIGHTS

Research background
The potential survival benefit of neoadjuvant chemotherapy (NC) in patients with advanced gastric cancer has been widely recognized.

Research motivation
With the development of minimally invasive surgery, which is represented by laparoscopy, the effect of NC on the safety of laparoscopic gastrectomy remains to be further explored.
Research objectives
To compare the short-term outcomes of laparoscopic total gastrectomy (LTG) after NC (NC-LTG) with LTG alone.

Research methods
A total of 92 patients who underwent NC-LTG and 381 patients who received LTG alone at the Chinese PLA General Hospital between September 2015 and September 2020 were retrospectively included in our study. We used propensity-score matching (PSM) to balance baseline bias. After 1:1 PSM, 73 patients were included in each group with no statistically significant difference in baseline characteristics.

Research results
The NC-LTG group exhibited a longer operation time and increased intraoperative blood loss compared to the LTG group. There were no significant differences in 30-d postoperative morbidity, 30-d severe complication rates, or anastomotic leakage rates. A multivariate analysis showed that an operation time greater than 240 min was an independent risk factor while NC was not an independent risk factor for postoperative complications in LTG.

Research conclusions
Despite a longer operation time and more blood loss after NC-LTG, which indicate surgical difficulty, NC-LTG exhibits acceptable short-term outcomes compared to LTG, illustrating the safety and feasibility of NC-LTG.

Research perspectives
Further research like multi-institutional retrospective study or randomized controlled trial study is needed to confirm our results and provide high-grade evidence for the appropriate application of NC-LTG.

REFERENCES
1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]
2 Sun D, Cao M, Li H, He S, Chen W. Cancer burden and trends in China: A review and comparison with Japan and South Korea. Chin J Cancer Res 2020; 32: 129-139 [PMID: 32410791 DOI: 10.21147/jissn.1000-9604.2020.02.01]
3 Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet 2016; 388: 2606 [PMID: 27894662 DOI: 10.1016/S0140-6736(16)32226-7]
4 Liu N, Xu Y, Rahememi-Azar AA, Abbott DE, Weber SM, Lidor AO. National Underutilization of Neoadjuvant Chemotherapy for Gastric Cancer. J Gastrointest Surg 2020; 24: 949-958 [PMID: 31792901 DOI: 10.1007/s11605-019-04439-y]
5 Terashima M, Yoshihata T, Boku N, Ito S, Tsuburaya A, Iwasaki Y, Fukagawa T, Tokunaga M, Sano T, Sasaki M; Stomach Cancer Study Group; Japan Clinical Oncology Group. Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Jpn J Clin Oncol 2020; 50: 528-534 [PMID: 32134452 DOI: 10.1093/jjco/hyaa005]
6 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
7 Ji J, Shen L, Li Z, Zhang X, Liang H, Xue Y, Wang Y, Zhou Z, Yu J, Chen L, Du Y, Li G, Xiao G, Wu D, Zhou Y, Dang C, He Y, Zhang Z, Sun Y, Li Y. LBA42 Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) vs postoperative chemotherapy of SOX or oxaliplatin with capcitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase III trial (RESOLVE trial). Ann Oncol 2019; 26 Suppl 4: S29-S30 [DOI: 10.1093/annonc/mdz394.033]
8 Kang YK, Youk JH, Park YK, Kim YW, Kim J, Ryu MH, Rha SY, Chung HJ, Kim IH, Oh SC, Yoo CH, Choi JH, Zang DY, Kim G, Lee Y, Noh SH. A phase III open label randomized study of neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1 (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY study). Ann Oncol 2019; 30 Suppl 5: S851-S934 [DOI: 10.1093/annonc/mdz394.032]
9 Yang X, Li S, Xie T, Lu Y, Guo X, Lin C. Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial). J Clin Oncol 2020; 38 [DOI: 10.1200/JCO.2020.38.4_suppl.280]
10 An JY, Kim KM, Kim YM, Cheong JH, Hyung WJ, Noh SH. Surgical complications in gastric...
cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. *Ann Surg Oncol* 2012; 19: 2452-2458 [PMID: 22395984 DOI: 10.1245/s10434-012-2267-9]

11 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Maurer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. *J Clin Oncol* 2010; 28: 5210-5218 [PMID: 21060024 DOI: 10.1200/JCO.2009.26.6114]

12 Claassen VHM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenburg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial. *Eur J Surg Oncol* 2018; 44: 613-619 [PMID: 29503129 DOI: 10.1016/j.ejso.2018.02.004]

13 Liu K, Yang K, Zhang W, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, Chen L, Hu J. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China. *Ann Surg* 2016; 263: 88-95 [PMID: 25647058 DOI: 10.1097/SLA.0000000000001488]

14 Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, Du X, Huang H, Hu J, Li G, Yu P, Li Y, Suo J, Zhao N, Zhang W, Li H, He H, Sun Y. Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS). Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. *JAMA Oncol* 2020; 6: 1590-1597 [PMID: 32815992 DOI: 10.1001/jamaoncol.2020.3152]

15 Hung WJ, Yang HK, Han SU, Lee YJ, Park JM, Kim JH, Kwon OK, Kong SH, Kim HI, Lee HJ, Kim W, Ryu SW, Jin SH, Oh SJ, Ryu KW, Kim MC, Ahn HS, Park YK, Kim YH, Hwang SH, Kim JW, Cho GS. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03. *Gastric Cancer* 2019; 22: 214-222 [PMID: 30128720 DOI: 10.1007/s10120-018-0864-4]

16 Lee H, Kim W, Lee J. Long-Term Outcomes of Laparoscopic vs Open Total Gastrectomy for Advanced Gastric Cancer: A Propensity Score-Matched Analysis. *Dig Surg* 2020; 37: 220-228 [PMID: 31269485 DOI: 10.1159/000501427]

17 Li Z, Liu Y, Bai B, Yu D, Lian B, Zhao Q. Surgical and Long-Term Survival Outcomes After Laparoscopic and Open Total Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. *World J Surg* 2019; 43: 594-603 [PMID: 30229382 DOI: 10.1007/s00268-018-4799-z]

18 Gambhir S, Inaba CS, Whealon M, Suja-ththa-Bhaskar S, Pejcinovska M, Nguyen NT. Short- and long-term survival after laparoscopic vs open total gastrectomy for gastric adenocarcinoma: a National database study. *Surg Endosc* 2021; 35: 1872-1878 [PMID: 32394166 DOI: 10.1007/s00464-020-07591-8]

19 Amia MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenson JD, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Bulch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. AJCC Cancer Staging Manual. 8th ed. New York: Springer. 2016 [DOI: 10.1007/978-3-319-40618-3]

20 Japanese Gastric Cancer Association. *Japanese gastric cancer treatment guidelines 2018* (5th edition). *Gastric Cancer* 2021; 24: 1-21 [PMID: 32060757 DOI: 10.1016/j.ogcanc.2019.10.004]

21 Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, Tsujuba Y, Satoh T, Yokomizo A, Fukuda H, Sasaki M. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. *Surg Today* 2016; 46: 668-685 [PMID: 26289837 DOI: 10.1007/s10595-015-1236-x]

22 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meier J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Kolprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Hess V, Illner, G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Lühr C, Bernhardt H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Beller S, Gaiser T, Oduncu FS, Günther M, Hoazeele W, Reichart A, Jäger E, Kraus T, Möglin S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD, FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel vs fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; 393: 1948-1957 [PMID: 30982686 DOI: 10.1016/S0140-6736(18)35257-1]

23 Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzen F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012; 379: 315-321 [PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4]

24 Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. *Br J Surg* 2014; 101: 653-660 [PMID: 24668391 DOI: 10.1002/bjs.9479]
Cui H et al. Efficiency of NC for LTG

10.1002/bjs.9484

25 Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasaki M, Morita S, Nomura T, Yamada M, Fujiwara Y, Kimura Y, Ikeda A, Kadokawa Y, Sano T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). *Gastric Cancer* 2020; 23: 1044-1052 [PMID: 31515693 DOI: 10.1007/s10120-019-00941-z]

26 Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Kahi T, Yoshihawa T, Ito Y, Kaji M, Kimura Y, Hiroo M, Yamada M, Kuriya A, Takagi M, Boku N, Sano T, Sasaki M, Stomach Cancer Study Group. Japanese Clinical Oncology Group. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). *Gastric Cancer* 2019; 22: 1044-1052 [PMID: 30827001 DOI: 10.1007/s10120-019-00941-z]

27 Li Z, Shan F, Ying X, Zhang Y, E JY, Wang Y, Ren H, Su X, Ji J. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. *JAMA Surg* 2019; 154: 1093-1101 [PMID: 31553463 DOI: 10.1001/jamasurg.2019.3473]

28 van der Wielen N, Straatman J, Daams F, Rosati R, Parise P, Weitz J, Reissfelder C, Diez Del Val I, Loureiro C, Parada-González P, Pintos-Martínez E, Mateo Vallejo F, Medina Achirica C, Sánchez-Pernate A, Ruano Campos A, Bonavina L, Asti ELG, Alonso Poza A, Gilsanz C, Nilsson M, Lindblad M, Gisbertz SS, van Berge Henegouwen MI, Fumagalli Romario U, De Pascale S, Akhtar K, Jaap Bonjer H, Cuesta MA, van der Peet DL. Open vs minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial. *Gastric Cancer* 2021; 24: 258-271 [PMID: 32736737 DOI: 10.1007/s10120-020-01109-w]

29 Shuai XM, Gao JB, Liu XH, Zhang P, Bai J, Cai KL, Wang GB, Tao KX. Clinical efficacy of neoadjuvant chemotherapy combined with laparoscopy-assisted radical gastrectomy for advanced gastric cancer. Zhonghua Xiaohua Waike Zazhi 2016; 215: 241-246 [DOI: 10.3760/cma.j.issn.1673-9752.2016.03.007]

30 Yan Y, Yang A, Lu L, Zhao Z, Li C, Li W, Chao J, Liu T, Fong Y, Fu W, Woo Y. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study. *Ann Surg Oncol* 2021; 28: 1428-1436 [PMID: 32862371 DOI: 10.1245/s10434-020-09070-9]

31 Zhang KC, Chen L. Difficulties and solutions of laparoscopic gastrectomy after neoadjuvant chemotherapy. Zhongguo Puwai Jicha Yu Linchuang Zazhi 2019; 26: 772-774

32 Feng D, Leong M, Li T, Chen L. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. *World J Surg Oncol* 2015; 13: 11 [PMID: 25634099 DOI: 10.1186/s12957-015-0444-6]

33 Wu L, Le G, Qin Y, Huang M, Chen J, Yang Y, Zhong J. Postoperative morbidity and mortality after neoadjuvant chemotherapy vs upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. *Cancer Manag Res* 2019; 11: 6011-6018 [PMID: 31307472 DOI: 10.2147/CMAJ.S203880]

34 Luo H, Wu L, Huang M, Jin Q, Qin Y, Chen J. Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis. *Medicine (Baltimore)* 2018; 97: e12932 [PMID: 30412102 DOI: 10.1097/MD.0000000000012932]

35 Ahn HS, Jeong SH, Son YG, Lee HJ, Im SA, Bang YJ, Kim HH, Yang HK. Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. *Br J Surg* 2014; 101: 1560-1565 [PMID: 25200278 DOI: 10.1002/bjs.9632]

36 Kim SH, Son SY, Park YS, Ahn SH, Park DJ, Kim HH. Risk Factors for Anastomotic Leakage: A Retrospective Cohort Study in a Single Gastric Surgical Unit. *J Gastric Cancer* 2015; 15: 167-175 [PMID: 26648414 DOI: 10.5230/jgc.2015.15.3.167]

37 Makuuchi R, Irino T, Tanizawa Y, Bando E, Kawamura T, Terashima M. Esophageojugal anastomotic leakage following gastrectomy for gastric cancer. *Surg Today* 2019; 49: 187-196 [PMID: 30317492 DOI: 10.1007/s00595-018-1726-8]

38 Kahi T, Mizusawa J, Katayama H, Kunisaki S, Sakuramoto S, Inaka N, Kinosita T, Iwasaki Y, Misawa K, Takiguchi N, Kaji M, Okitus H, Yoshikawa T, Terashima M; Stomach Cancer Study Group of Japan Clinical Oncology Group. Single-arm confirmatory trial of laparoscopic-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. *Gastric Cancer* 2019; 22: 999-1008 [PMID: 30788750 DOI: 10.1007/s10120-019-00929-9]

39 Kodera Y, Yoshida K, Kumamaru H, Kakeji Y, Hiki N, Etoh T, Honda M, Miyata H, Yamashita Y, Seto Y, Kitano S, Konno H. Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan. *Gastric Cancer* 2019; 22: 202-213 [PMID: 29427039 DOI: 10.1007/s10120-018-0795-0]

40 Fukagawa T, Kahi T, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, Kinosita T, Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee SW, Yasuda T, Sasaki M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). *Gastric Cancer* 2018; 21: 68-73 [PMID: 28194522 DOI: 10.1007/s10120-017-0701-1]
